Therapeutic Advances in Psychopharmacology

Papers
(The median citation count of Therapeutic Advances in Psychopharmacology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Relationship between resilience and mental health among COVID-19 bereaved people: the mediating role of dual process coping88
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review52
Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years’ experience at a UK high-secure hospital45
Prevalence and predictors of inappropriate prescribing in outpatients with severe mental illness43
Analysis of the clinical characteristics of olanzapine-induced acute pancreatitis42
History repeating: guidelines to address common problems in psychedelic science40
The missing link? Pharmacists’ perspectives on discontinuation of long-term antidepressants: a qualitative study38
The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial33
Disrupted emotion regulation and spontaneous neural activity in panic disorder: a resting-state fMRI study30
Comment on: History repeating: guidelines to address common problems in psychedelic science24
Who is prescribed valproate and how carefully is this treatment reviewed in UK mental health services? Data from a clinical audit24
Incidence of hyperthyroidism in patients with bipolar or schizoaffective disorder with or without lithium: 21-year follow-up from the LiSIE retrospective cohort study23
Psychotropic medications versus non-pharmacologic approaches for managing behavioural and psychological symptoms in Australian aged care residents with dementia: general practitioners’ and physicians’23
Reasons for discontinuing and restarting lithium multiple times: a case-register study based on the South London and Maudsley NHS Foundation Trust Clinical Record Interactive Search system22
The efficacy of antipsychotics in the treatment of physical aggressive behavior in patients with dementia in nursing homes22
Corrigendum to “Managing medical and psychiatric multimorbidity in older patients”21
Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry19
Brugada syndrome: should we be screening patients before prescribing psychotropic medication?19
Plain Language Summary of Publication: A comparison of once-monthly and once-every-2-months injectable formulations of aripiprazole in people with schizophrenia18
Reasons for admission to a general medical hospital for patients taking clozapine18
Antipsychotics and structural brain changes: could treatment adherence explain the discrepant findings?16
Monoclonal antibody precision therapy targeting inflammation for bipolar disorder: a narrative review16
Risperidone-induced priapism: a case report and literature review15
Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review15
Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey15
Clinical outcomes following switching antipsychotic treatment due to market withdrawal: a retrospective naturalistic cohort study of pipotiazine palmitate injection (Piportil Depot) discontinuation, s15
Estimation of cardiac QTc intervals in people prescribed antipsychotics: a comparison of correction factors14
Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications14
Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand13
Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine13
Risperidone-induced neuroleptic malignant syndrome: a case report13
Impact of CYP1A , CYP2C19 , CYP2D6 , CYP3A4 , CYP3A5 13
Will psilocybin lose its magic in the clinical setting?13
Corrigendum to ‘Comment on: History repeating: guidelines to address common problems in psychedelic science’12
Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review11
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia10
Anticholinergic action is rarely a good thing10
Duration of prior psychotic illness and clozapine response: a retrospective observational study using electronic health records9
High-dose olanzapine in treatment-resistant schizophrenia: a systematic review8
The role of empathy in antidepressant withdrawal8
Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies8
Decreased citalopram concentration caused by enzyme induction effect of rifampin: a case report8
Incorporation of a specialist mental health clinical pharmacist within a primary care network: patient referrals, prescribing decisions, and clinical outcomes8
Treating job-related stress with psychedelic group therapy: a case series on group ketamine-assisted psychotherapy for healthcare workers and first responders8
Corrigendum to “Psychedelic Assisted Therapy as a Complex Intervention: Implications for clinical trial design”7
Clozapine blood level assessment using a point-of-care device: feasibility and reliability7
Preliminary data from a 4-year mirror-image and multicentre study of patients initiating paliperidone palmitate 6-monthly long-acting injectable antipsychotic: the Paliperidone 2 per Year study7
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series7
The role of flumazenil in generalised anxiety disorder: a pilot naturalistic open-label study with a focus on treatment resistance7
Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression7
Tardive dyskinesia: understanding current challenges in diagnosis and treatment6
Risperidone ISM®: review and update of its usefulness in all phases of schizophrenia6
Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen Area6
Increased amisulpride serum concentration in a patient treated with concomitant pregabalin and trazodone: a case report6
Drug safety in older patients with alcohol use disorder: a retrospective cohort study6
The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics6
Predicting rTMS treatment response in schizophrenia using interpretable machine learning: a SHAP-based analysis6
The cardiovascular safety of tricyclic antidepressants in overdose and in clinical use6
Ketamine-assisted therapy within a community of practice: a novel approach to disordered eating6
Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?5
Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan5
Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics5
Altered orbitofrontal and pars opercularis cortical thickness in betel quid dependence chewers5
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence5
Psychosocial interventions to improve adherence in depressed and anxious older adults prescribed antidepressant pharmacotherapy: a scoping review5
Ketamine dosing formula in treatment-resistant bipolar depression4
Drug utilization in geriatric psychiatric patients in the emergency department—a cohort study under real-world conditions4
Managing medical and psychiatric multimorbidity in older patients4
Olanzapine for the treatment of ICU delirium: a systematic review and meta-analysis4
Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review4
The place of long-acting injectable antipsychotics in the treatment of schizophrenia4
Psychotropic medications adherence status and its determinants among older adults with severe affective and psychotic disorders: a multicenter cross-sectional study4
Classic psychedelics, health behavior, and physical health4
The past, present and future of anticholinergic drugs3
Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation3
Frequency of anticholinergic drug use in patients treated with aripiprazole once-monthly: a 2-year cohort study using European healthcare databases3
Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis3
Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study3
Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an in silico modelling study3
Sublingual asenapine for agitation in malabsorptive states: three patient cases3
Serum cytokine variations among inpatients with major depression, bipolar disorder, and schizophrenia versus healthy controls: a prospective ‘true-to-life’ study3
From model psychosis to rapid antidepressant: a historical and conceptual review of ketamine’s psychiatric history3
Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery3
Oral contraceptive formulation and socio-cognitive performance: a short communication3
Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis3
Preventing and treating delirium in clinical settings for older adults3
Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis3
0.028753042221069